Specifically, in different types of both hematological (e.g., diffuse large B-cell lymphoma) and solid cancers (e.g., neuroblastoma, melanoma, breast, prostate and lung cancer), gain-of-function mutations or the overexpression of EZH2 increases H3K27me3, which represses genes encoding tumor-specific antigens and MHC molecules [103,104,105,106]. This evidence concerns the gene EZH2 and neoplasm.